Contraception for Specific Populations

Contraception for Specific Populations

CEU Statement: Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants - March 2017

29 March 2017

This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.

This document is up-to-date

CEU Statement: Sodium Valproate and Pregnancy Risks (February 2016)

01 February 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) recently launched a toolkit for healthcare professionals (HCPs) regarding sodium valproate in order to communicate its teratogenic effects. The CEU recommends that all HCPs be prepared to provide information about and access to effective contraception for women who have undergone treatment with valproate-related medicines.

This document is up-to-date

Weight, Obesity and Contraception

CEU Statement: Weight and contraception (April 2017)

24 April 2017

This statement summarises the available evidence regarding how contraception may affect a woman’s weight and how a woman’s weight may affect contraceptive efficacy. Looking at each method individually, the CEU advises clinicians on what proven and theoretical associations exist between contraception and weight.

This document is up-to-date

Young People

CEU Statement: Provision of LARC methods to young women in the UK (July 2015)

01 July 2015

The recent article in the Telegraph newspaper has highlighted the complex issues surrounding sexual activity in young women in the UK. Whilst it is true that the legal age of consent to sexual activity in the UK is 16 years, surveys suggest that almost one in three young people will have had sexual intercourse by this age.

This document is up-to-date